EGFR and hepatocellular carcinoma: Moreover, PLAGL2 overexpression plays a vital role in hepatocellular carcinoma and induces tumor metastasis via EGFR-HIF-1/2α signaling, and cell lines with high PLAGL2 expression have erlotinib resistance, which can be a biomarker for erlotinib therapy [23].